Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.

@inproceedings{Chau2017RamucirumabA,
  title={Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.},
  author={Ian Chau and Markus Peck-Radosavljevic and Christophe Borg and P Malfertheiner and Jean François Seitz and Joon Oh Park and Boong Yeol Ryoo and Chin‐lien Yen and Masatoshi Kudo and Ronnie Tung-ping Poon and Davide Pastorelli and J Julian Blanc and Hyun Cheol Chung and Ari David Baron and Takuji Okusaka and Zhanglin Lin Cui and Allicia C. Girvan and Paolo Benjamin Abada and Ling Yang and Andrew X. Zhu},
  year={2017}
}

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…